Q-omics provides the consensus-scored PTH2R profile across patient tissues and cancer cell-line models. PTH2R expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PTH2R is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, PTH2R RNA expression shows 15,457 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, KICH, and KIRP as cancer lineages where PTH2R shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTH2R — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTH2R survival associations across molecular data types. PTH2R RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTH2R RNA expression–survival associations across cancer types. High PTH2R expression shows unfavorable associations in UVM and ACC, but favorable associations in THCA, KIRC, SKCM and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PTH2R RNA expression.
This table summarizes PTH2R tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PTH2R. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTH2R shows lower tumor expression in KICH and BRCA and higher tumor expression in HNSC, LUSC, LIHC and STAD. The KICH box plot shows higher PTH2R RNA expression in normal versus tumor tissue (log2 FC = −3.915, t-test p < 0.001).
This table shows molecular features associated with PTH2R in patient tissues and cancer cell lines. In patient samples, PTH2R shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, PTH2R RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
